Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

Inclusion Criteria:

* Patient with histologically proven CD20+ diffuse large B cell lymphoma (WHO Classification).
* Aged from 18 to 59 years, eligible for transplant.
* Patient not previously treated.
* Age adjusted International Prognostic Index equal to 2 or 3.
* Having previously signed a written informed consent.
* Women of childbearing potential currently practicing an adequate method of contraception.

Exclusion Criteria:

* Any other histological type of lymphoma.
* Any history of treated or non-treated indolent lymphoma.
* Central nervous system or meningeal involvement by lymphoma.
* Contra-indication to any drug contained in the chemotherapy regimens.
* Poor renal function (creatinin level\>150mmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
* Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l, unless related to bone marrow infiltration.
* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
* Any serious active disease (according to the investigator's decision).
* HIV, HTLV1 or HBV related disease.
* Any organ transplantation before inclusion.
* Pregnant women.